JP2016502537A5 - - Google Patents

Download PDF

Info

Publication number
JP2016502537A5
JP2016502537A5 JP2015545156A JP2015545156A JP2016502537A5 JP 2016502537 A5 JP2016502537 A5 JP 2016502537A5 JP 2015545156 A JP2015545156 A JP 2015545156A JP 2015545156 A JP2015545156 A JP 2015545156A JP 2016502537 A5 JP2016502537 A5 JP 2016502537A5
Authority
JP
Japan
Prior art keywords
concentration
formulation
nr2b9c
tat
trehalose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015545156A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016502537A (ja
JP6427104B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/071755 external-priority patent/WO2014085349A1/en
Publication of JP2016502537A publication Critical patent/JP2016502537A/ja
Publication of JP2016502537A5 publication Critical patent/JP2016502537A5/ja
Application granted granted Critical
Publication of JP6427104B2 publication Critical patent/JP6427104B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015545156A 2012-11-28 2013-11-25 Tat−NR2B9cの凍結乾燥製剤 Expired - Fee Related JP6427104B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261730952P 2012-11-28 2012-11-28
US61/730,952 2012-11-28
PCT/US2013/071755 WO2014085349A1 (en) 2012-11-28 2013-11-25 Lyophilized formulation of tat-nr2b9c

Publications (3)

Publication Number Publication Date
JP2016502537A JP2016502537A (ja) 2016-01-28
JP2016502537A5 true JP2016502537A5 (enExample) 2016-12-22
JP6427104B2 JP6427104B2 (ja) 2018-11-21

Family

ID=50828392

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015545156A Expired - Fee Related JP6427104B2 (ja) 2012-11-28 2013-11-25 Tat−NR2B9cの凍結乾燥製剤

Country Status (18)

Country Link
US (1) US20140162957A1 (enExample)
EP (1) EP2925338B8 (enExample)
JP (1) JP6427104B2 (enExample)
KR (1) KR102166374B1 (enExample)
CN (2) CN109106941A (enExample)
AU (1) AU2013352437B2 (enExample)
CA (1) CA2892965C (enExample)
DK (1) DK2925338T3 (enExample)
ES (1) ES2725598T3 (enExample)
HR (1) HRP20190707T1 (enExample)
HU (1) HUE043820T2 (enExample)
LT (1) LT2925338T (enExample)
MX (1) MX365325B (enExample)
PL (1) PL2925338T3 (enExample)
PT (1) PT2925338T (enExample)
SI (1) SI2925338T1 (enExample)
TR (1) TR201905787T4 (enExample)
WO (1) WO2014085349A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
CN106661126B (zh) 2014-05-28 2021-12-10 诺诺公司 TAT-NR2B9c的氯盐
WO2015181757A1 (en) * 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
US20190064147A1 (en) * 2015-01-18 2019-02-28 Biogen Ma Inc. Formulations and screening of biological therapeutic agents
JP2019522675A (ja) * 2016-04-27 2019-08-15 ▲拝▼西欧斯(北京)生物技▲術▼有限公司 興奮製神経毒性に関連した損傷の治療方法
CN106619170A (zh) * 2016-10-26 2017-05-10 暨南大学 包含stp和生长因子的活性组合物及其化妆品或护肤品
CN110627877A (zh) * 2019-09-25 2019-12-31 成都奥达生物科技有限公司 一种psd-95抑制剂
JP2023511057A (ja) * 2020-01-09 2023-03-16 ノノ インコーポレイテッド 脳卒中及び関連疾患を治療するためのプラスミン耐性ペプチド

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605884A (en) * 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
EP1709084A4 (en) * 2003-12-23 2008-05-28 Nono Inc POLYPEPTIDES FOR MODULATING BINDING OF TRP-CHANNEL PROTEINS AND TRP-ASSOCIATED PROTEINS
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
WO2007002395A1 (en) * 2005-06-23 2007-01-04 Arbor Vita Corporation Methods and compositions for modulating cox
US8633160B2 (en) * 2005-12-30 2014-01-21 Nono Inc. Small molecule inhibitors of PDZ interactions
SG171670A1 (en) * 2006-05-05 2011-06-29 Transtech Pharma Inc Rage fusion proteins, formulations, and methods of use thereof
EP1884521A1 (en) * 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
CN102202677A (zh) * 2008-09-03 2011-09-28 阿尔伯维塔公司 治疗疼痛的活性剂和方法
US8099602B2 (en) * 2008-09-26 2012-01-17 Mykonos Software, Inc. Methods for integrating security in network communications and systems thereof
CA3018494C (en) * 2009-06-10 2021-12-07 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
PT2440230T (pt) * 2009-06-10 2021-02-03 Nono Inc Regimes de tratamento para tratamento de doenças neurológicas
ES2655112T3 (es) * 2010-08-12 2018-02-16 Nono Inc. Tratamiento de una lesión penetrante en el cerebro

Similar Documents

Publication Publication Date Title
JP2016502537A5 (enExample)
RU2016150678A (ru) ХЛОРИДНАЯ СОЛЬ ПЕПТИДА TAT-NR2B9с, КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
JP2013079270A5 (enExample)
HRP20190707T1 (hr) Liofilizirana formulacija tat-nr2b9c
MX2019012081A (es) Proteina de fusion del factor de crecimiento 21 de fibroblastos humanos (hfgf21), metodo de preparacion de la misma y su uso.
ATE538774T1 (de) Pharmazeutische formulierungen und verfahren zur behandlung von atemwegsinfektionen
EP3928800A3 (en) Dry powder composition comprising long-chain rna
MX337932B (es) Proteinas f del vrs modificadas y metodos de uso de las mismas.
JP2014051497A5 (enExample)
NZ711567A (en) Antibody formulations
BR112017015852A2 (pt) forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1
CL2013000306A1 (es) Productos de confiteria envasados no congelados para la preparacion de un confite estaticamente congelado que comprende un sistema de proteina coagulada que incluye caseina y proteina de suero donde el sistema de proteina coagulada se puede obtener sometiendo una composicion de proteinas lacteas con un ph entre 5,6 y 6,5 a un tratamiento termico de 80-90 ºc o por sobre 90 º hasta 160 ºc por 1 segundo hasta 60 minutos; y metodo de producción de dicho producto.
JP2013508315A5 (enExample)
EA201490653A1 (ru) Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств
UA117480C2 (uk) Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
EP4706400A3 (en) Heat sterilized high protein compositions comprising whey protein and at least one component selected from (i) a saccharide, (ii) a phosphate and (iii) a citrate
JP2015533509A5 (enExample)
MX389336B (es) Formulacion farmaceutica.
BRPI0911678B8 (pt) maleato de orvepitant cristalino anidro, composição farmacêutica compreedendo o dito maleato e uso do mesmo para o tratamento ou profilaxia de doenças do sistema nervoso central
EP2398804A4 (en) ACID ADDITION SALT FROM UDENAFIL, METHOD OF MANUFACTURING THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH
WO2016019350A3 (en) Microscale bioprocessing system and method for protein manufacturing from human blood
WO2016066722A3 (en) Bacteriophage combinations for human or animal therapy
UA103834C2 (ru) Капсулированный белоксодержащий продукт и способ его получения
NZ591738A (en) Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella
WO2011104555A3 (en) Process for the preparation of sunitinib malate form i